Cefaclor Extended-Release Tablets Rx
Generic Name and Formulations:
Cefaclor 375mg, 500mg; ext-rel tabs.
Various generic manufacturers
Indications for Cefaclor Extended-Release Tablets:
Susceptible mild to moderate infections including acute exacerbations of chronic bronchitis, secondary infections of acute bronchitis, pharyngitis/tonsillitis, uncomplicated skin and skin structures.
Take with meals. Swallow whole. Cefaclor ext-rel tab 500mg twice daily clinically equivalent to caps 250mg three times daily. ≥16yrs: Bronchitis: 500mg every 12 hrs for 7 days. Pharyngitis/tonsillitis: 375mg every 12 hrs for 10 days. Skin and skin structures: 375mg every 12 hrs for 7–10 days.
<16yrs: not recommended.
Penicillin or other allergy. Discontinue if colitis occurs and treat. Severe renal dysfunction. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln. Potentiated by probenecid. Monitor warfarin. ER: antagonized by concomitant (within 1 hr) aluminum or magnesium-containing antacids.
Headache, GI upset, rash, blood dyscrasias, hepatic dysfunction, cough, CNS stimulation, serum-sickness-like reactions.
Formerly known under the brand names Ceclor CD (ext-rel tabs); Ceclor (caps, susp); Raniclor (caps).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Cognitive Impairment May Predict Persistent Psychosis in Ketamine Users
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders